1. Home
  2. ELWS vs NXL Comparison

ELWS vs NXL Comparison

Compare ELWS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Earlyworks Co. Ltd.

ELWS

Earlyworks Co. Ltd.

BUY

Current Price

$7.10

Market Cap

19.8M

Sector

N/A

ML Signal

BUY

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.61

Market Cap

18.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELWS
NXL
Founded
2018
2010
Country
Japan
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8M
18.6M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
ELWS
NXL
Price
$7.10
$0.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
26.6K
177.0K
Earning Date
03-02-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,083,071.00
$156,931.00
Revenue This Year
N/A
$38.28
Revenue Next Year
N/A
$185.71
P/E Ratio
N/A
N/A
Revenue Growth
145.52
N/A
52 Week Low
$1.64
$0.54
52 Week High
$10.50
$3.87

Technical Indicators

Market Signals
Indicator
ELWS
NXL
Relative Strength Index (RSI) 64.84 36.27
Support Level $5.40 $0.61
Resistance Level $6.34 $0.77
Average True Range (ATR) 0.81 0.06
MACD 0.09 0.01
Stochastic Oscillator 90.00 2.06

Price Performance

Historical Comparison
ELWS
NXL

About ELWS Earlyworks Co. Ltd.

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: